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and valvular heart disease. However, there have been few studies on the risk
for development of AF in an elderly cohort, taking into account ECG vari-
ables.
Aims: We aimed to evaluate the clinical and ECG predictors of preva-
lent AF in a large population-based prospective cohort study. The clinical
and ECG workups were realized at admission and after 4 years of follow-
up.
Methods: The study is part of the Three City Study (COVADIS), which
included subjects aged 65 years and above and not institutionalised. The prev-
alence of AF at baseline was assessed in 4234 patients.
Results: The overall prevalence was 2,33%. Based on multivariable
analyses, the HR was 2.08 [95% CI: 1.07-4.54], p=0.03) for male gender.
Age above 75 years was associated with an increase of AF prevalence (HR
1.92 [95% CI: 1.24-2.97], p=0.003) as well as history of stroke (HR=2.90
[95% CI: 1.15-6.56], p=0.02), history of AF (HR, 2.74 [95% CI: 1.12-
6.20], p=0.02). None of the other classical clinical risk factors was associ-
ated with AF prevalence. Q waves and ST segment depression on the base-
line ECG were associated with an increased prevalence of AF: HR, 2.70
[95% CI: 2.13-6.44], p<0.001) and HR, 12.6 [95% CI: 6.56-23.8],
p<0.001, respectively.
Conclusion: In a contemporary cohort of elderly subjects, ECG variables
suggesting CAD, history of previous AF, history of stroke, age and gender
were predictors of AF prevalence.
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Purpose: The prevalence of atrial fibrillation (AF) is increasing world-
wide, affecting 4.5 million people in the European Union, and up to 1 million
people in France. Yet, cardioversion practices (CV) are not well documented.
The RHYTHM-AF international observational study aimed to describe
regional patient populations and CV practices.
Methods: Consecutive adult candidates for CV with documented recent
AF were enrolled from hospitals in 10 countries. Information on French
patients was collected between September 2010 and April 2011 in 25 centers.
Descriptive statistics were used to document patient characteristics and CV
practices.
Results: Among the first 492 French enrolled patients, mean age was
69 years, 65% were male, 57% were hypertensive, 16% diabetic and 16%
presented with a history of chronic heart failure while a quarter (26%) showed
heart failure symptoms. Transthoracic and transesophageal echocardiography
were available in 70% and 30% of patients, respectively.
Over half (56%) of all patients underwent an attempt at CV; and the
majority of them (80%) underwent electrical CV. The remaining 20% under-
went pharmacological CV, most (81%) using amiodarone IV. At hospital dis-
charge, the median length of stay was 46 hours (IQR: 26-84) for electrical CV
and 203 hours (IQR: 91-409) for pharmacological CV. Also at discharge, 73%
of patients were in normal sinus rhythm, 92% were prescribed anticoagulation
drugs, and 63% anti-arrhythmic drugs. Adverse events occurred in 3% of
patients and in-hospital mortality was 0.6%.
Conclusions: In France, observations suggest that current cardiology
ward management of recent onset AF involves attempted CV in just over
half of patients considered for CV. Among those cardioverted, treatment is
oriented towards electrical CV, with a median length of in-hospital stay of
2 days. While electrical CV seems to be the preferred option of French
cardiologists, amiodarone IV is nonetheless their first pharmacological
treatment choice.
Table – Results
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Background: Both rate- and rhythm-control are accepted management
strategies for atrial fibrillation (AF). The frequency of success of either
strategy and the impact of control on symptomatic status of AF patients have
not been described,
Methods: RealiseAF was a multicentre, international, observational, cross-
sectional survey of patients with any AF history in the previous 12 months,
performed in 2009-10 by random sampling of cardiologists and internists. It
aimed to describe the characteristics, symptoms, quality of life (QoL), and
management patterns of AF patients, and determine the frequency of AF con-
trol (defined as sinus rhythm or AF with resting heart rate 80 beats per
minute [bpm]).
Findings Of 10546 patients enrolled, 10 523 were eligible for analysis and
9665 evaluable for AF control. AF was controlled in 59.0% of patients (sinus
rhythm 26.5%, AF 80 bpm 32.5%), and uncontrolled in 41.0%. Symptom
prevalence in the previous 7 days was lower in controlled than uncontrolled
AF (55.7% vs 68·4% respectively; p<0.001) and similar for patients in sinus
rhythm and patients in AF 80 bpm (54·8% vs 56.4%; p=0.23). On the day of
the visit, AF-related functional impairment (European Heart Rhythm Associa-
tion Class >1) was observed in 67.4% of controlled and 82.1% of uncontrolled
AF patients (p<0.001). QoL (measured using the EQ-5D tool) was better for
patients with controlled versus uncontrolled AF for all measures: visual analog
Total Cardioverted No CV
Total (N (%)) 492 
(100%)
277 (56%) 215 
(44%)
1st detected AF 169 
(36%)
92 (33%) 77 
(40%)
Paroxsymal AF 94 
(20%)
39 (14%) 55 
(28%)
Persistent AF 144 
(31%)
97 (35%) 47 
(24%)
CHADS2 score (mean, (SD)) 1.3 
(1.1)
1.4 (1.1) 1.1 
(1.0)
Mode of Cardioversion
Total PhCV ECV No CV
Total (N (%)) 492 
(100%)
55 
(11%)
226 
(46%)
215 
(44%)
LoS, hours (median (IQR)) 48 
(22-144)
203 
(91-409)
46
 (26-84)
62 
(4-134)
Time to CV, hours (median 
(IQR))
21 
(16-49)
24 
(5-74)
21
 (18-46)
–
